ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

About this update from Oryzon Genomics Sa

[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"All resolutions were approved","length":29,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":29,"olType":false},{"type":"text","content":"MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Madrid. A total of 24,030,812 of the Company's issued and outstanding ordinary shares (representing 36.5312% of the share capital) were at the Meeting, either in person or represented by proxy.","length":546,"tagName":"p"},{"type":"text","content":"The Company's shareholders approved all of the resolutions listed below, proposed by the Board of Directors at the Company's Extraordinary General Meeting, with favorable votes ranging from 94% to 97%.","length":209,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Appointment and re-election of directors.","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Re-election of Mr. Carlos Buesa as executive director.","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"Re-election of Mr. Manuel López-Figueroa as independent director.","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointment of Mr. Konstantinos Alataris as independent director.","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointment of Mr. Luis Sánchez Quintana as independent director.","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointment of Ms. Montserrat Vendrell as independent director.","length":63,"tagName":"p"}]},{"val":[{"type":"text","co...

More updates from Oryzon Genomics Sa